Abstract: Nucleic acid molecules and compositions comprising: a nucleic acid sequence that encodes IL-12 p35 subunit or a functional fragment thereof and/or a nucleic acid sequence that encodes IL12 p40 subunit or a functional fragment thereof, are disclosed. The nucleic acid molecules and compositions further comprising a nucleic acid sequence that encodes an immunogen are also disclosed. Method of modulating immune response and methods of inducing an immune response against an immunogen are disclosed. Therapeutic and prophylactic vaccination methods are also disclosed.

Abstract: The invention provides methods for increasing or decreasing antibody production in vivo by inhibiting or promoting the activity of fibroblast growth factor-2 (FGF2) respectively.

Abstract: Methods and compositions relating to medical (e.g., therapeutic) use of CD38 agonists are provided. In some embodiments, the present invention provides methods and compositions relating to use of CD38 in the treatment of cancer, particularly to enhance the efficacy of antibody therapy directed to cancer cells.

Abstract: Described are methods of treating a subject after acute trauma to the head, viral encephalitis, or other causes of acute neurodegeneration, and/or after acute vascular insults, including ischemic and hemorrhagic strokes, the method comprising administering inhibitors of BACE1; an inhibitory oligonucleotide targeting BACE1; and/or an inhibitory oligonucleotide targeting APLP2. Also described are methods for treating a subject who is at high risk for head trauma, including administering a prophylactically effective amount (i.e., an amount sufficient to reduce the risk of developing or reduce the severity or duration of symptoms of head trauma) of one or more of an inhibitor of BACE1; an inhibitory oligonucleotide targeting BACE1; or an inhibitory oligonucleotide targeting APLP2.

Abstract: Novel methods of treating neuroendocrine tumors are provided. In one embodiment, the method comprises administering to a subject in need thereof a therapeutically effective dose of a Wnt antagonist. In one embodiment, the Wnt antagonist is an anti-FZD antibody. In another embodiment, the Wnt antagonist is a soluble FZD receptor polypeptide. In a further embodiment, the Wnt antagonist is an anti-Wnt antibody.

Abstract: The invention provides buffered formulations of adalimumab. The formulations comprise a buffer comprising an acetate salt, mannitol, glacial acetic acid, sodium chloride, and polysorbate 80. The formulations have an acidic pH, and enhance the thermal, conformational and colloidal stability of antibodies, including the adalimumab antibody.

Abstract: In a method for treating an affected skin region of a patient having a skin disorder, a vasodilation composition is applied to an affected skin region of a patient, the affected skin region exhibiting a skin disorder characterized by at least one abnormal blood vessel, and the affected skin region is then treated so as to non-invasively disrupt tissue architecture, e.g., by inducing ischemia, of the at least one abnormal blood vessel. A vasoconstriction composition can then be applied to the skin region to cause vasoconstriction of the at least one blood vessel in order to promote healing.

Abstract: A method for delivering an antifungal agent to a nail surface or a surface of a body excluding an oral cavity includes the step of adding the antifungal agent and a penetration enhancer containing composition sequentially or simultaneously to the nail surface or the surface of the body to form a further composition. Penetration through the nail or the surface of the body of the antifungal agent is enhanced by the penetration enhancer, and the penetration enhancer is a metal chlorite salt.

Abstract: Antimicrobial compositions, especially those useful when applied topically, particularly to mucosal tissues (i.e., mucous membranes), including a cationic antiseptic such as biguanides and bisbiguanides such as chlorhexidine and its various salts including but not limited to the digluconate, diacetate, dimethosulfate, and dilactate salts; polymeric quaternary ammonium compounds such as polyhexamethylenebiguanide; silver and various silver complexes; small molecule quaternary ammonium compounds such as benzalkoium chloride and alkyl substituted derivatives; di-long chain alkyl (C8-C18) quaternary ammonium compounds; cetylpyridinium halides and their derivatives; benzethonium chloride and its alkyl substituted derivatives; and octenidine. The compositions can also include an enhancer component, a surfactant, a hydrophobic component, and/or a hydrophilic component.

Abstract: Discloses herein are high concentration antibody formulations comprising an anti-sclerostin immunoglobulin and an acetate salt and/or an acetate buffer and methods of use.

Abstract: The present invention provides a method of producing an aqueous solution containing an N—C8-22 acyl acidic amino acid and/or a salt thereof and having pH 8.4-9.5, including the first step for reacting an acidic amino acid and/or a salt thereof with a C8-22 fatty acid chloride in a water solvent at pH 10-13 to form an N—C8-22 acyl acidic amino acid salt, and the second step for adjusting the pH of the aqueous solution after the first step to 8.4-9.5.

Abstract: Improved formulations for topical treatment that ensure at least localized transdermal or systemic delivery of an active agent through skin, nails or hair follicles are disclosed.

Abstract: The present invention relates to a surfactant composition comprising at least one alkylglycoside having the formula CnGm wherein C is an alkyl group; n is the number of carbon atoms in the alkyl group and is 14 to 24; said alkyl group being unbranched or branched, saturated or unsaturated, derivatised or non-derivatised; G is a saccharide residue containing 5 to 6 carbon atoms; and m is a number from 4 to 20. It further also relates to its use and application in detergents, emulsifying agents, wetting agents, anti-aggregation and stabilising composition and dispersants comprising the same.

Abstract: Compositions including at least one Omega-3 fatty acid ester and at least one surface active agent are provided; wherein the compositions form micelles when in contact with an aqueous medium. Also provided is a method of administering to a subject such a composition, wherein the at least one Omega-3 fatty acid ester forms micelles when in contact with an aqueous medium, and the bioavailability of the at least one Omega-3 fatty acid ester is substantially independent of a food effect. The compositions are useful for treating cardiovascular conditions or disorders in a subject and for reducing side effects associated with the ingestion of Omega-3 fatty acid esters. Further provided are also various dosage forms for administering the compositions and use of the compositions in functional foods. Provided herein are also kits with instructions on how to administer the compositions.

Abstract: The invention provides a colon cleansing solution comprising: a) 300 to 800 mmol per litre ascorbate anion provided by a mixture of: (i) ascorbic acid and (ii) one or more salts of ascorbic acid the components (i) and (ii) being present in a molar ratio of from 1:4.5 to 1:7.0; and b) 10 to 200 g per litre polyethylene glycol. The invention also provides methods and kits associated with, or making use of the solutions, and compositions for the preparation of the solutions.

Abstract: Disclosed herein is an insulinotropic peptide multi-dose aqueous parenteral pharmaceutical composition and use thereof. A long-term storage formulation of the insulinotropic peptide can be obtained via the method of the present disclosure. The pharmaceutical composition of the present disclosure comprises: insulinotropic peptide, insulinotropic peptide analogue and derivative; pharmaceutically acceptable tonicity modifier (stabilizer); pharmaceutically acceptable preservative; and pharmaceutically acceptable dissolution enhancer and pharmaceutically acceptable buffer solution. The pharmaceutical composition of the insulinotropic peptide is used in the preparation of drugs for treating diabetes and adiposis.

Abstract: The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which is capable of binding with high affinity to a neurotransmitter transporter. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interests and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of imaging agents to the cells for diagnostic purposes.

Abstract: Provided herein is a means for increasing protein retention in blood. The protein retention in blood is increased by forming a conjugate of a protein and chondroitin produced by a microorganism having chondroitin-producing capability and/or chondroitin synthesized with a chondroitin synthase.

Abstract: The present invention relates to ligand-therapeutic agent conjugate compounds, silicon linkers for the conjugate compounds, compositions, methods for making them, and methods for the treatment of cancer using the conjugate compounds. The silicon-based linkers described herein can be used to deliver desired therapeutic agents to particular cells or tissue types targeted by the ligand.

Abstract: The invention provides methods for selective targeting of live cells, which have undergone or are undergoing radiation or chemotherapy, at a site of interest with a cell-penetrating polypeptide. In one embodiment of the invention, the method comprises contacting the live cells with a cell-penetrating polypeptide comprising cell-penetrating determinants so that the cell-penetrating polypeptide binds extracellular DNA near or around the live cells so as to form a complex or association therewith such that the complex or associated polypeptide-DNA so bound bind the live cells and penetrates the live cells thereby selectively targeting live cells at a site of interest with a cell-penetrating polypeptide.

Abstract: This document provides methods and materials related to treating cancer (e.g. skin cancer). For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g. ABRAXANE®/anti-VEGF polypeptide antibody complexes) to treat cancer (e.g. skin cancer) are provided.

Abstract: The invention relates to glycoengineered antibodies and antibody-conjugates. In particular, the invention relates to an antibody conjugate, prepared from IgG antibody comprising at least two N-linked glycosylation sites on the combination of a single heavy chain and single light chain. The invention further relates to methods for the preparation of the antibody-conjugates according to the invention. In particular, the invention relates to an antibody-drug conjugate that is conjugated to different toxins, and the a process for the preparation thereof.

Abstract: The invention relates to compositions of vault complexes for use as delivery agents for hydrophobic and/or aqueous insoluble therapeutic compounds. In one aspect, provided herein is a vault complex comprising a modified major vault protein (MVP), wherein the modified major vault protein comprises a fusion peptide, wherein said fusion peptide is fused to the N-terminus of the major vault protein, and wherein said peptide provides enhanced sequestering of a hydrophobic and/or aqueous insoluble therapeutic compound within the vault complex.

Abstract: Provided herein is chitosan-derivative nanoparticle comprising chitosan functionalized with a cationic amino acid and a hydrophilic polyol; and methods of making and using same, e.g., for gene delivery in vivo.

Abstract: The present invention provides a method for providing modified mRNAs of reduced immunogenicity and/or immunostimulatory capacity for use in protein replacement therapy. The invention further provides modified mRNAs and pharmaceutical compositions comprising the modified mRNAs according to the invention for use in protein replacement therapy.

Abstract: Urea-based photosensitizers, which target prostate-specific membrane antigen (PSMA) for imaging and targeted therapy of PSMA-expressing tumors and cancers are disclosed.

Abstract: Porphyrin compounds useful in the field of magnetic resonance imaging (MRI) as contrast agents. The compounds are relatively lipophilic porphyrins, include one or more enzyme-reactive functional groups, and are cell membrane permeable. Relatively lipophilic group(s) can be enzymatically released within a cell to produce a relatively hydrophilic porphyrin compound.

Abstract: The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.

Abstract: The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount offree macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.

Abstract: The presently disclosed subject matter provides non-invasive methods for imaging, quantifying ?7 nicotinic cholinergic receptors, and diagnosing a disease or condition associated with ?7-nAChRs. Methods for preparing radiolabeled derivatives of dibenzothiophene and compounds provided thereof also are provided.

Abstract: Multifunctional chelators, metal complexes thereof, compositions thereof, and methods of making and use in diagnostic imaging and treatment of cellular disorders.

Abstract: The disclosure is related to a chemical structure, a preparation and an imaging method of a tumor imaging tracer, especially to a SPECT radionuclide-labeled trimeric cyclic RGD peptide: 99mTc-4P-RGD3, which functions as a ligand to be combined with integrin ?v?3 receptor in tumor for tumor imaging. The preparation includes linking HYNIC-OSu with 4P-RGD3 to form HYNIC-4P-RGD3 and then chelating HYNIC with 99mTc to create 99mTc-4P-RGD3. Animal biodistribution and imaging experiments reveal higher uptake in tumor and lower uptake in normal organs, therefore the disclosure can improve image quality, Through animal metabolic experiments, the original form of 99mTc-4P-RGD3 can be still excreted without the evidence of further metabolites in urine and feces.

Abstract: Compositions and methods for assessing inflammation in a subject. The preset disclosure provides compositions for labeling leukocytes with a 19F-containing perfluoropolyether molecule ex vivo. In some examples, the leukocytes are obtained from the patient, enriched in a whole blood fraction, and then labeled. The labeled cells may be re-introduced into the patient. The leukocytes may accumulate at a site of inflammation, thus permitting non-invasive evaluation of inflammation in patients. The present methods provide a tool for assessing inflammation in a wide variety of autoimmune diseases and may have particular utility in intestinal diseases such as Crohn's disease, ulcerative colitis, inflammatory bowel disease, and cardio myositis.

Abstract: A method of sterilizing a material, said method comprising the steps of: (a) introducing a solution comprising peroxyacetic acid into a hot gaseous stream to produce a peroxyacetic acid vapor; and (b) contacting such peroxyacetic acid vapor with the material to be sterilized.

Abstract: The invention relates to a sterilizers and methods of sterilization of an instrument. The sterilizer includes an ozone generator, an air mover, an oxygen concentrator, and a controller. The ozone generator, which is housed by the sterilization chamber, generates at least one plasma field. The air mover circulates air through the sterilization chamber. The oxygen concentrator delivers oxygen-concentrated air to the sterilization chamber. The controller communicates with the ozone generator, the air mover, and the oxygen concentrator. The sterilizer may also include a battery to power the components of the sterilizer. A portable case may house the sterilizer.

Abstract: The present disclosure is generally related to systems, methods and devices for providing ozone treatment of multiple medical devices including passageways. In particular the systems, methods and devices may attach to multiple medical devices and clean, disinfect and/or sterilize the inner space of the tubes, including the areas most prone for bacteria buildup. A multi-channel ozone treatment device has an ozone operating system and a distribution line that splits into a plurality of distribution channels to distribute ozone to a plurality of ozone ports in a gas-tight compartment. A multi-port connector unit for connecting to a plurality of passageways in the gas-tight compartment is further disclosed.

Abstract: The present disclosure is generally related to devices, methods and systems for cleaning, disinfecting and/or sterilizing a medical device, medical hoses and tubes and accessories thereof with ozone gas, in particular the disclosure relates to devices, methods and systems with multiple receptacles for providing closed-loop fluid pathways to distribute ozone gas to inner passageways and the outer compartments of medical devices. The devices in accordance with an embodiment of the disclosure have two or more receptacles for distributing ozone gas, a gas-tight compartment, an ozone operating system, and one or more connector units configured to fluidly migrate ozone in closed-loop treatment systems.

Abstract: The invention relates to the sterilization of a load of goods with hydrogen peroxide vapor in a closed space. The method involves a sequence of creating a sub-atmospheric pressure in a sterilization chamber, introduction of vaporized hydrogen peroxide and the use of a gas circulation device within the sterilization chamber, whereby the output of the gas circulation device is controlled according to the pressure in the sterilization chamber. A uniform and consistent distribution of hydrogen peroxide throughout the load is achieved.

Abstract: A system for treating an enclosed area may include a plurality of fogging devices each including a housing, a fluid reservoir, a compressor coupled to the fluid reservoir, an atomizing nozzle in fluid communication with the fluid reservoir, a first wireless transceiver, and a first processor coupled to the compressor and the wireless transceiver. A wireless communications device may include a second wireless transceiver and a second processor to identify the fogging devices within the enclosed area based upon the first and second wireless transceivers, determine respective fogging times for the fogging devices based upon a size of the enclosed area and a number of the foggers identified within the enclosed area, and initiate a treatment cycle during which, on a coordinated schedule, the first processor of each fogging device causes its associated compressor to dispense fluid into the enclosed area via the atomizing nozzle for the respective fogging time.

Abstract: A device a method, and a computer program for use in a device (40) for washing, disinfecting and/or sterilizing medical, dental, laboratory and/or pharmaceutical goods. The device comprises a chamber (41) for receiving the goods, a door (42) associated with the chamber (41) and a processing circuitry for creating and storing a track record of at least one parameter of the washing, disinfecting and/or sterilizing process performed by the device (40). The user interface (44, 45) is operable by the user to cause the process circuitry to electronically sign the track record, and wherein the signing of the track record is associated with at least one condition on the device (40). The device, method and computer program facilitates an easy and secure signing of a track record directly on the device.

Abstract: The invention relates to compositions for producing hydrophilicized polyurethane foams, in particular for wound management, wherein the composition, containing a polyurethane dispersion and specific additives, is frothed and dried.

Abstract: A method for preparing a hydrogel coating for a wound dressing to provide the wound dressing with non-adhesion properties without interfering with the bioactivity of the agents contained in the wound dressing. The hydrogel coating is formed by treating the substrate with O2 plasma before applying a hydrogel precursor solution onto the substrate, and then curing the hydrogel precursor onto the substrate to form the hydrogel coating on the surface of the substrate. Hydrogel coatings for a wound dressing and wound dressings having a hydrogel coating are further described.

Abstract: A superabsorbent polymer which has excellent initial absorbency and keeps water from flowing out under pressure even after the passage of a long period of time, in which the superabsorbent polymer keeps water from flowing out under pressure even after the passage of a long period of time to exhibit excellent absorbency, and also has an anti-caking property under conditions of high temperature and high humidity to improve storage stability, is provided. The superabsorbent polymer composition of the present invention may be used to improve physical properties of a variety of diapers, potty training pants, incontinence pads, etc., thereby being applied to production of personal absorbent hygiene products having high absorbency and excellent storage stability under conditions of high temperature and high humidity.

Abstract: The invention describes a bone cement with antimycotic efficacy based on organic polymers, such as polymethylmethacrylate. The bone cement comprises an antimycotic agent, in particular amphotericin B, that is released from the polymerised bone cement in the presence of water or aqueous media, such as body fluids. According to one alternative, the antimycotic agent is present in particulate form and is encapsulated, at least in part, by a mixture of at least one 1-methylamino-1-deoxy sugar alcohol and at least one fatty acid. In addition, a method for the production of a mixture comprising an antimycotic agent, such as amphotericin B particles, and 1-methylamino-1-deoxy sugar alcohol and at least one fatty acid is proposed. Preferably, the antimycotic agent is encapsulated, at least partially, by 1-methylamino-1-deoxy sugar alcohol and at least one fatty acid.

Abstract: Disclosed herein are compositions and methods for making germanium-based glass polyalkenoate cements. Also disclosed are methods for their use as bone cements for bone augmentation procedures.

Abstract: The invention relates to a method that includes: placing a bone material, containing hydroxyapatite and organic substances, in contact with an extraction liquid that gives rise to a first liquid phase, containing said organic substances and possibly impurities extracted from said bone material, and a second solid hydroxyapatite phase, containing said hydroxyapatite; and separating said liquid phase and said solid hydroxyapatite phase. Said extraction liquid is an aqueous extraction solution brought to a temperature between 150° C. and 300° C. and a pressure between 150 kPa and 350 kPa.

Abstract: Intraocular lens materials are disclosed. They are soft and very deformable and have a high refractive index, and a high glistening resistance in fully hydrated state. They are particularly suitable for making wet-packed intraocular lenses (IOLs) which can be delivered through sub 2.0 mm incisions.

Abstract: Described herein are injectable alloplastic implant compositions that are particularly useful for soft tissue defect augmentation. The compositions include microparticles, such as polymethylmethacrylate particles, and collagen as a suspending agent, wherein the collagen contains a reduced amount of low molecular weight gelatine compared to high molecular weight collagen. By controlling the molecular weight of the collagen in the compositions, the injectability, stability, and antigenicity of the alloplastic implant compositions can be improved.

Abstract: A bone-repairing agent excellent in workability and applicability to clinical surgical techniques and having a drastically enhanced bone formation rate, obtained by including an elastin hydrolysate in a complex of DNA and at least one selected from the group consisting of protamine, a protamine derivative, and a protamine hydrolysate can be provided. A medical or dental material for bone formation using this bone-repairing agent can be provided.

Abstract: The present disclosure relates generally to silk fibroin and unlysed platelet compositions. The compositions are useful for a variety of medical uses such as wound healing or repair and soft tissue repair or augmentation.